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Inhalant Use and Inhalant Use Disorders in the United States
M
ore than 22 million Americans age 12 and older have used inhalants, and every year more than 750,000 use inhalants for 
the first time. Despite the substantial prevalence and serious toxicities of inhalant use, it has been termed “the forgotten 
epidemic.” Inhalant abuse remains the least-studied form of substance abuse, although research on its epidemiology, neuro-
biology, treatment, and prevention has accelerated in recent years. This review examines current findings in these areas, identi-
fies gaps in the research and clinical literatures pertaining to inhalant use, and discusses future directions for inhalant-related 
research and practice efforts. 
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I
nhalant abuse refers to the intentional inhalation of vapors from commercial 
products or specific chemical agents to achieve intoxication. Abusers may 
inhale vapors directly from a container, from a bag into which a substance 
has been placed, or from a rag soaked with a substance and then placed over the 
mouth or nose (American Psychiatric Association [APA], 2000). Intoxication 
occurs rapidly and is short-lived, although some abusers repeatedly or continuously 
self-administer inhalants to maintain a preferred level of intoxication.
Inhalant abuse and dependence criteria parallel the generic substance abuse and 
dependence diagnostic criteria outlined in the Diagnostic and Statistical Manual 
of Mental Disorders, 4th Edition (DSM-IV; APA, 2000). The criteria do not 
include withdrawal symptoms, although some evidence suggests a characteristic 
withdrawal syndrome (Perron et al., 2009a). Amyl nitrate, other nitrite vasodilators, 
and nitrous oxide are sometimes abused by inhalation, but the criteria specifically 
exclude them from the list of substances considered.
Glue, shoe polish, toluene, spray paints, gasoline, and lighter fluid are among 
the inhalants most commonly abused by young people (Substance Abuse and 
Mental Health Services Administration [SAMHSA], 2008b). However, hundreds 
of products containing single substances or mixtures that can produce intoxication 
if inhaled are commercially available (Table 1). The huge variety of products that 
emit psychoactive vapors poses difficulties for classification. The current approach 
of grouping inhalants by form, product type, or intended use has conceptual and 
heuristic limitations. Classification into groups that share pharmacological properties 
and distinctive patterns of abuse may be more useful, but is unavailable at present 
because little is known about the pharmacologic effects of many abused vapors.RESEARCH REVIEWS—INHALANT USE AND INHALANT USE DISORDERS • 19
Inhalant use 
disproportion-
ately afflicts 
the poor, men-
tally ill, and 
juvenile- and 
criminal-jus-
tice involved.
Although inhalant abuse is common and associated with 
harmful outcomes that may rival or exceed those of other 
psychoactive drugs (Dinwiddie, 1994; 1998; Sharp and 
Rosenberg, 2005), inhalants remain the least-studied 
class of psychoactive agents (Balster, 1996). There are 
no clearly effective treatment interventions reported 
in the clinical research literature. Here we discuss the 
consequences of inhalant abuse and review potential 
treatments under investigation and harm reduction 
measures that appear to be effective.
EPIDEMIOLOGY OF INHALANT USE
The most informative surveys of inhalant use are the 
Monitoring the Future (MTF) survey, the Youth Risk 
GLUES AND ADHESIVES
Airplane glue  Toluene, ethyl acetate
Other glues and cements  Hexane, toluene, methyl chloride, acetone, methyl ethyl ketone, methyl butyl  
      ketone, benzene, xylene, trichloroethylene, tetrachloroethylene, chloroform
AEROSOLS
Spray paint  Butane, propane (U.S.), fluorocarbons, toluene, hydrocarbons, xylene
Hair spray  Butane, propane (U.S.), chlorofluorocarbons
Deodorant; air freshener  Butane, propane (U.S.), chlorofluorocarbons
Analgesic spray  Chlorofluorocarbons
Asthma spray  Chlorofluorocarbons
Fabric spray  Butane, trichloroethane
PC cleaner  Dimethyl ether, hydrofluorocarbons
Video head cleaner  Ethyl chloride
ANESTHETICS
Gaseous  Nitrous oxide
Liquid  Halothane, enflurane, desflurane, isoflurane
Local  Ethyl chloride
CLEANING AGENTS
Dry cleaning  Tetrachloroethylene, trichloroethane
Spot remover  Xylene, petroleum distillates, chlorohydrocarbons
Degreaser  Tetrachloroethylene, trichloroethane, trichloroethylene
Lacquer; thinners  Acetone, methanol, ethyl acetate, methyl chloride, toluene
SOLVENTS AND GASES
Nail polish remover  Acetone, ethyl acetate, toluene (rarely)
Paint remover  Toluene, methylene chloride, methanol, acetone, ethyl acetate
Paint thinner  Petroleum distillates, esters, acetone
Correction fluid and thinner  Trichloroethylene, trichloroethane, isoparaffins
Fuel gas  Butane, isopropane
Lighter fluid  Butane, isopropane
Fire extinguisher  Bromochlorodifluoromethane
Gasoline  Benzene, n-hexane, toluene, xylene
TABLE 1. Commonly Abused Inhalant Products and Their Constituents
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Behavior Survey (YRBS), and the National Survey on 
Drug Use and Health (NSDUH) (Table 2). They reveal:
•  An estimated 9 percent of the U.S. population age 12 
and older—22.5 million people—has used an inhalant 
for its psychoactive properties at least once (NSDUH);
•	Inhalant use tends to start early, with 58 percent of 
users reporting first use by the end of ninth grade 
(MTF);
•	Thirteen percent of students in grades 9 through 12 
reported having ever used an inhalant on the 2007 YRBS;
•  Fewer students in older grades than in younger grades 
(15.7 percent in 9th grade, 9.9 percent in 12th grade) 
reported having ever used an inhalant on the 2008 
MTF, suggesting that many who start using inhalants 
early drop out of school;
•	Most inhalant users initiate the behavior quite young, 
and most discontinue it quickly (Crocetti, 2008; 
d’Abbs and MacLean, 2008; SAMHSA, 2008b; 
Siqueira and Crandall, 2006). For example, the 2006 
MTF indicated that on average, half of 8th, 10th, and 
12th graders who had ever used inhalants had not 
done so during the past year (Johnston et al., 2007). 
However, as noted above, young people who drop out 
of school appear to continue using inhalants at higher 
rates than those who stay;
•	White and Hispanic students reported lifetime use 
rates (14.4 percent) that were about twice those of 
African Americans (8.5 percent; YRBS);
•  Important risk factors for inhalant use among middle 
and high school students include low levels of parental 
education and a lack of intention to complete 4 years 
of college (MTF);
•	More than half of eighth graders saw the regular use of 
inhalants as a “great risk,” but only a third attributed 
the same amount of danger to using an inhalant once 
or twice (MTF).
The MTF and NSDUH have produced conflicting 
findings regarding whether gender influences adolescent 
inhalant use. The 2006 MTF indicated that more 8th- 
and 10th-grade girls than boys, and more 12th-grade 
boys than girls, had used an inhalant (Johnston et al., 
2007). In contrast, the NSDUH and its predecessor, the 
National Household Survey on Drug Abuse (NHSDA), 
have consistently shown equal use rates among boys and 
girls (Neumark, Delva, and Anthony, 1998; SAMHSA, 
2006; Wu, Pilowsky, and Schlenger, 2004).
Inhalant, use disproportionately afflicts subpopula-
tions including the poor, mentally ill, and juvenile- and 
criminal-justice involved (Howard et al., 1999). For 
example, studies have documented inhalant use rates of:
•	34.3 percent among 475 juvenile probationers surveyed 
in Utah (Howard and Jenson, 1999). The earlier that 
individuals had initiated use and the more frequently 
they used, the higher the likelihood that use was associ-
ated with significant psychosocial dysfunction;
•	36.9 percent of 723 Missouri youth surveyed in a 
residential treatment center for antisocial behavior 
(Howard et al., 2008);
•  approximately 18 percent of 847 adolescents referred to 
a treatment program for substance abuse or behavioral 
problems (Sakai et al., 2004). In addition, 10 percent of 
adult substance abusers surveyed in a treatment center 
had used inhalants more than five times (Compton et 
al., 1994).
Efforts have been made to identify subtypes of inhal-
ant users, which could facilitate the identification of 
at-risk individuals, assessment, and treatment planning 
(Perron, Vaughn, and Howard, 2007; Vaughn, Perron, 
and Howard, 2007). These studies have found elevated 
inhalant use rates among youths who experienced a 
recent major depressive episode (SAMHSA, 2008a) and 
a subgroup of adolescents who used inhalants to “self-
medicate” for unhappiness and anxiety (Perron, Vaughn, 
and Howard, 2007). These latter youths exhibited sig-
nificantly more polydrug use, psychiatric comorbidity, 
and antisocial behavior than did two other classes of 
adolescent inhalant users. 
Low monetary cost and ease of access probably 
contribute to the concentration of inhalant use among 
younger children and adolescents; low-income and 
unemployed adults; people living in isolated rural or 
reservation settings; and people housed in institutions 
such as psychiatric hospitals, prisons, and residential 
treatment centers. Inhalants can also be purchased and 
used without arousing the suspicion of parents, sales-
people, school or law enforcement professionals, social 
service workers, or health care providers (Anderson and 
Loomis, 2003). Few people, for example, think of butane 
cigarette lighters, computer air dusters, nail polish, nail 
polish remover, or paint thinner as items that can be 
abused for their psychoactive effects; if challenged, young 
people can often offer plausible benign explanations for 
having these items.
 
EPIDEMIOLOGY OF INHALANT USE  
DISORDERS 
Inhalant use disorders are among the least prevalent 
substance use disorders. In nationally representative 
Studies have 
produced a 
range of esti-
mates of inhal-
ant users’ risk 
of developing 
an inhalant use 
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Survey
Name
Design, Target  
Population, and  
Frequency of  
Administration
Inhalant Question Estimates of Life-
time Prevalence 
of Inhalant Use
Limitations and Strengths 
of the Surveys
Monitoring  
the Future
Annual cross-sectional 
survey since 1975 for 
12th-graders and since 
1991 for 8th- and 10th-
graders
“On how many occasions (if any) have 
you sniffed glue, or breathed the con-
tents of aerosol spray cans, or inhaled 
any other gases or sprays in order to 
get high in your lifetime?”
“During the past 12 months?”
“During the past 30 days?”
2010, by grade: 
8th: 14.5 %
10th: 12.0%
12th: 9.0%
School-based survey 
misses dropouts and  
truants. Uses single 
omnibus item for  
inhalant use assessment.
Provides data on  
perceived danger and  
disapproval of inhalants. 
Youth Risk 
Behavior  
Survey
Semi-annual cross-
sectional survey con-
ducted since 1991 for 
grades 9 through 12
Middle school version: “Have you ever 
sniffed glue, or breathed the contents 
of spray cans, or inhaled any paints or 
sprays to get high?” Response options: 
Yes/No.
High school version: “During your life, 
how many times have you sniffed glue, 
breathed the contents of aerosol spray 
cans, or inhaled any paints or sprays 
to get high?” Response options: 0 
times; 1 or 2 times; 3 to 9 times; 10 to 
19 times; 20 to 30 times; 40 or more 
times.
2009, by grade: 
9–12: 11.7% 
10th: 12.5%
12th: 9.1%
School-based survey 
misses dropouts and 
 truants.
Provides data on comor-
bid risk behavior and 
state-specific findings.
National  
Survey on Drug 
Use  
and Health 
Annual cross- 
sectional survey of  
U.S. residents 12  
and older conducted 
since 1971
“These next questions are about liq-
uids, sprays, and gases that people 
sniff or inhale to get high or to make 
them feel good. Have you ever, even 
once, inhaled [INHALANT NAME] for 
kicks or to get high? Response options: 
Yes/No for the following inhalants: a) 
amyl nitrite “poppers,” locker room 
odorizers or “rush;” b) correction fluid, 
degreaser, or cleaning fluid; c) gaso-
line or lighter fluid; d) glue, shoe pol-
ish, or toluene; e) halothane, ether, or 
other anesthetics; f) lacquer thinner or 
other paint solvents; g) lighter gases, 
such as butane or propane; h) nitrous 
oxide or “whippets; ” i) spray paints; j) 
some other aerosol spray; and k) any 
other inhalants besides the ones that 
have been listed.
2007 by grade:
8th: 12.0%
10th: 10.7%
12th: 8.2%
9–12: 10.8%
12 years or 
older: 9.1% or 
22,470,000 U.S. 
residents.
Household survey that 
captures dropouts and 
truants, but misses insti-
tutionalized populations 
and respondents younger 
than 12. 
Provides state-specific 
estimates.
TABLE 2. Nationally Representative Surveys of Inhalant Use22 • ADDICTION SCIENCE & CLINICAL PRACTICE—JULY 2011
surveys, youths reporting symptoms that would permit a 
diagnosis of inhalant abuse or dependence have included 
0.6 percent of the 15- to 24-year-old participants in the 
1992 National Comorbidity Survey (NCS) (Anthony, 
Warner, and Kessler, 1994), and 0.2 percent of the 12- to 
17-year-olds who responded to the 2002–2003 NHSDA 
(Wu, Pilowsky, and Schlenger, 2004). The past-year 
prevalence of inhalant use disorder among adult par-
ticipants in the 2001–2002 National Epidemiologic 
Survey on Alcohol and Related Conditions was 0.02 
percent (Grant et al., 2004). 
Studies have produced a range of estimates of inhalant 
users’ risk of developing an inhalant use disorder. At the 
lower end, an analysis of NCS data yielded an estimate 
that 7.9 percent of 15- to 24-year-olds with a history of 
inhalant use were dependent (Anthony, Warner, and 
Kessler, 1994). Similarly, Wu, Pilowsky, and Schlenger 
(2004) found that 6 percent of 12- to 17-year-olds who 
reported past-year use on the 2000 and 2001 NHSDA 
surveys met criteria for past-year inhalant abuse, and 4 
percent met criteria for past-year dependence. Higher 
estimates for rates of inhalant use disorders among indi-
viduals with histories of inhalant use include:
• 18 percent among adults who participated in the nation-
ally representative National Epidemiologic Survey on 
Alcohol and Related Conditions (Wu and Howard, 
2007b);
•		47 percent among a community sample of 162 young 
adults in St. Louis, Missouri (Ridenour, Bray, and 
Cottler, 2007).
The wide divergence in prevalence estimates may 
reflect the presence of elevated-risk groups in some sam-
ples. For example, Howard and Perron (2009) found a 
47 percent prevalence of inhalant use disorders among 
279 juvenile justice-involved inhalant users in Missouri. 
In the Wu, Pilowsky, and Schlenger NHSDA-based 
study (2004), adolescents who had initiated inhalant 
use before age 15 were five to six times as likely as those 
who had started later to be diagnosed with inhalant 
dependence in the year prior to the survey. 
CONSEQUENCES OF INHALANT USE 
Inhalant use is associated with a large number of adverse 
effects and psychosocial outcomes. 
Acute Effects
Inhalant intoxication produces a syndrome similar to 
alcohol intoxication, consisting of dizziness, incoor-
dination, slurred speech, euphoria, lethargy, slowed 
reflexes, slowed thinking and movement, tremor, blurred 
vision, stupor or coma, generalized muscle weakness, 
and involuntary eye movement (APA, 2000). Inhalant 
use can result in chemical and thermal burns ( Moreno 
and Beierle, 2007), withdrawal symptoms (Keriotis and 
Upadhyaya, 2000), persistent mental illness (Jung, Lee, 
and Cho, 2004), and catastrophic medical emergencies 
such as ventricular arrhythmias leading to “sudden sniff-
ing death” ( Avella, Wilson, and Lehrer, 2006; Bowen, 
Daniel, and Balster, 1999). Inhalant intoxication also 
increases the risk for fatal injuries from motor vehicle 
or other accidents (Bowen, Daniel, and Balster, 1999).
 
Neurological and Cognitive Effects 
Studies of occupationally exposed workers laid the 
foundation for much of what we know about inhalant-
related cognitive deficits. Morrow and colleagues (1997) 
found significant learning and memory impairments in 
journeyman painters relative to controls and evidence 
that many patients’ inhalant-related cognitive problems 
were slow to resolve (Morrow, Steinhauer, and Condray, 
1996; 1998). 
Even a single occupational exposure leading to 
inhalant intoxication can produce long-term memory 
problems and processing speed impairments (Stollery, 
1996), an ominous finding given that inhalant abuse 
is characterized by exposures to neurotoxins at much 
higher levels than those typically incurred in occupational 
exposures (Bowen, Wiley, and Balster, 1996).
Early research with recreational inhalant users noted 
that, similar to the findings with occupational exposures, 
these individuals have memory, attention, and judg-
ment deficits compared with controls and polydrug 
users (Hormes, Filley, and Rosenberg, 1986; Korman, 
Trimboli, and Semler, 1980). Maruff and colleagues 
(1998) found that current inhalant users performed worse 
than former users and controls in a test of visual-spatial 
memory that challenges the test taker to remember the 
location in which a symbol briefly flashed on a computer 
screen. Tenebein and Pillay (1993) found diminished 
brain activity in response to visual and auditory events, a 
possible marker for neurological dysfunction, in 8 of 15 
inhalant users 9 to 17 years of age, even though the youths 
had no clinical evidence of neurological abnormalities. 
Subsequent studies have disclosed that recurrent 
inhalant intoxication can lead to neurological disorders, 
including Parkinsonism, impaired cognition due to deg-
radation of brain cells (encephalopathy) or loss of brain 
cells (cerebral atrophy), and loss of muscle strength and 
Motor deficits 
observed in 
mice exposed 
to toluene 
imply long-
lasting brain 
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coordination due to damage to the cerebel-
lum (cerebellar ataxia) (e.g., Finch and Lobo, 
2005; Gautschi, Cadosch, and Zellweger, 
2007). Imaging studies of inhalant abusers 
have documented thinning of the corpus 
callosum (the band of nerve fibers joining 
the cerebral hemispheres) and lesions of the 
white matter that facilitates communication 
between brain cells (Finch and Lobo, 2005; 
Gautschi, Cadosch, and Zellweger, 2007). 
Regional reductions in cerebral blood flow 
are observable with functional magnetic 
resonance imaging (fMRI) after 1 year of 
inhalant use (Okada et al., 1999; Yamanou-
chi et al., 1998). Other radiologic abnormali-
ties found in inhalant users include areas of 
reduced MRI signal strength (hypointensi-
ties) in the thalamus and basal ganglia (Lub-
man, Yücel, and Lawrence, 2008) and irregular uptake of 
radiolabeled pharmaceuticals in single-photon emission 
computed tomography (SPECT) studies (Küçük et al., 
2000). Lubman and colleagues (2008) reviewed recent 
clinical and neuroimaging studies of chronic inhalant 
abusers, documenting significant cognitive deficits, 
structural abnormalities in specific brain areas (e.g., 
periventricular, subcortical, and white matter), and 
reduced brain perfusion and blood flow.
Animal models have been helpful for studying acute 
and chronic biobehavioral effects of inhalants. They 
have shown that toluene and other inhalants can have 
reversible disruptive effects on response rates in behavior 
modification protocols; most of these effects appear to 
be greater after binge patterns of exposure than after 
lower levels of exposure (see Bowen et al., 2006, for 
review). In one of the few animal studies to examine the 
impact of binge-pattern exposures on higher cognitive 
processes, Bowen and McDonald (2009) reported that 
mice exposed to high concentrations of toluene (3,600 
and 6,000 parts per million) for 30 minutes per day for 
40 days (similar to the amounts chronic abusers inhale) 
demonstrated long-lasting motor deficits on a waiting-
for-reward task. This result implies the presence of long-
term brain damage, possibly resulting from cerebellar 
insult or cortical cell loss. Further animal trials are needed 
to identify toluene’s impact on cognition so that these 
toluene-related impairments can be recognized early 
and measures can be initiated to prevent potentially 
extensive neurological damage. Additional preclinical 
studies suggest that toluene and 1,1,1-trichloroethane 
(TCE) impair learning, memory, and attention (e.g., 
von Euler et al., 2000).
Effects on Organs Other Than the Brain
Evidence is mounting that inhalants can cause chronic 
medical problems affecting multiple organ systems 
(Figure 2). Animal studies, case reports, and small 
clinical investigations have implicated inhalant use in 
liver, heart, and kidney toxicity; bone demineraliza-
tion; bone marrow suppression; and reduced immunity 
(T-cell responsivity) (e.g., Karmakar and Roxburgh, 
2008; Takaki et al., 2008). Diminished plasma and red 
blood cell levels of selenium and zinc have also been 
noted, potentially impairing immune function and 
increasing the risk for infectious disease (Zaidi et al., 
2007). O’Brien, Yeoman, and Hobby (1971) reported 
a case of liver and kidney failure in a 19-year-old who 
had sniffed glue for 3 years, and Wiseman and Banim 
(1987) diagnosed irreversible congestive heart failure in 
a 15-year-old patient who had sniffed glue for 2 years. 
Inhalants can also cause peripheral neuropathy lead-
ing to chronic pain and vision-impairing optic nerve 
damage (e.g., Twardowschy et al., 2008).
Several recent studies suggest that inhalant abuse 
is associated with serious pulmonary dysfunction and 
disease.  An epidemiological study of 29,195 adults aged 
35 to 49 participating in the NSDUH found that dura-
tion of inhalant abuse was significantly positively associ-
ated with likelihood of having experienced tuberculosis, 
bronchitis, asthma, and sinusitis (Han, Gfroerer, and 
Colliver, 2010).  Cayir and colleagues (2011) compared 
Compared with the brain of an individual with no history of inhalant abuse (A), that of a chronic toluene 
abuser (B) is smaller and fills less of the space inside the skull (the white outer circle in each image). 
Courtesy of Neil Rosenberg, M.D., NIDA Research Report (NIH 05-3818).
FIGURE 1. Brain Atrophy in a Toulene Abuser
Adult inhalant 
abusers have 
higher rates of 
major depres-
sion, suicidal 
ideation and 
attempts, and 
anxiety and 
substance use 
disorders.
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18 volatile solvent abusers with 18 control subjects (all of 
whom were tobacco smokers), noting that radioisotope 
pulmonary clearance was significantly accelerated in 
the solvent abuser group. The authors concluded that 
alveolo-capillary membrane dysfunction may follow 
inhalant abuse. A recent death of an 18-year-old man 
due to bilateral pneumonia following inhalation of a 
computer keyboard cleaner has also raised concerns 
about potential pulmonary consequences of inhalant 
abuse (Schloneger, Stull, and Singer, 2009).
 
Psychosocial Effects
Workers occupationally exposed to inhalants experience 
relatively high post-exposure levels of depression and 
anxiety (Morrow et al., 2000). Condray and colleagues 
(2000) found that journeyman painters were significantly 
more likely than controls (41 percent versus 16 percent) 
to meet lifetime criteria for a mood disorder and that 
virtually all painters who met criteria for a mood dis-
order experienced their first episode after starting their 
painting careers.
Relatively little is known about the natural history 
of inhalant use, inhalant use disorders, and associated 
psychiatric and psychosocial comorbidities in the general 
population. Clinical, criminological, and general popula-
tion studies have identified robust associations between 
lifetime inhalant use, other drug use, and mental health 
disorders or symptoms. For example, SAMHSA (2005) 
estimated that youths who had used inhalants by ages 
12 or 13 were nearly five times as likely than nonusing 
peers to have used another psychoactive drug. Associa-
tions between early-onset inhalant use and risk for later 
heroin and intravenous drug use (Storr, Westergaard, 
and Anthony, 2005; Wu and Howard, 2007a), antisocial 
behavior, and polydrug abuse have also been identified 
(SAMHSA, 2005).
Studies of adults in substance abuse treatment and 
in the general population indicate that inhalant users 
have higher rates of major depression, suicidal ideation 
and attempts, anxiety disorders, and other substance 
use disorders than nonusers of inhalants (Howard et 
al., 2010a; 2010b). Wu and Howard (2007b) and Wu, 
Howard, and Pilowsky (2008) documented dramatically 
elevated rates of mood and anxiety disorders, personality 
disorders, and substance use disorders in a nationally 
representative sample of U.S. inhalant users. Inhalant 
use and inhalant use disorders also appear to raise the 
odds for stressful life events such as having troubles at 
school or with a boss or co-worker, being fired, or being 
arrested or sent to jail (Dinwiddie, 1994; 1998).
Some researchers have questioned whether inhal-
ant use contributes directly to subsequent drug use and 
adverse psychosocial outcomes, arguing instead that 
it may be a general indicator of a deviant disposition 
(Howard and Jenson, 1999; 2010a; 2010b). Published 
reports suggest that childhood and adolescent inhalant 
use may be a “red flag” signaling membership in a sub-
group of antisocial youths that is marked by high levels 
of psychiatric symptoms, polydrug use, and psychosocial 
impairment, as well as earlier onset of behavior problems 
and a wider range of antisocial conduct than are typical 
of nonusers of inhalants (Howard and Jenson, 1999; 
Howard et al., 1999; 2008; Freedenthal et al., 2007; 
Jacobs and Ghodse, 1988; McGarvey, Canterbury, and 
Waite, 1996). Additional studies are needed to evalu-
ate how inhalant abuse contributes to the etiology of 
psychiatric disorders and related mental, emotional, 
and physical disabilities.
FIGURE 2. Organs Damaged by Inhalant Exposure
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FUTURE RESEARCH
Inhalant abuse is one of few types of substance abuse for which demon-
strably effective treatment interventions are largely absent from the clinical 
research literature. Specific areas for future research include:
•  Ethnographic studies of cross-national patterns of inhalant use, includ-
ing products (agents) used and consequences of use;
• Longitudinal studies of the trajectory of inhalant use and inhalant use 
disorders, including factors that predict initiation, escalation, mainte-
nance, and cessation of use (e.g., Perron et al., 2009b);
• Investigations of the clinical manifestations of inhalant use disorders, 
including the nature and characteristics of tolerance and withdrawal 
symptoms across a wide range of abused inhalants; 
• Studies of acute and long-term consequences of inhalant use; 
• Psychometric evaluations of the reliability, validity, and latent structure 
of DSM-IV inhalant abuse and dependence diagnoses (e.g., Howard et 
al., 2001; Howard and Perron, 2009); 
• Efficacy trials of combined pharmacological and psychosocial interven-
tions for adolescents and adults with inhalant use disorders; 
• Taxonomic efforts to identify subtypes of inhalant users and abusers; 
• Evaluations of promising inhalant use prevention interventions; and
• Evaluations of product modification, law enforcement, and other supply-
side approaches to reducing the availability of abused inhalants in the 
social and physical environments.
Effects on the Fetus
Maternal inhalant use during pregnancy may produce 
effects in offspring similar to those seen in fetal alcohol 
syndrome (Jones and Balster, 1998; Bowen and Hanni-
gan, 2006; Hannigan and Bowen, 2010). One study, for 
example, reported high rates of head and facial deformi-
ties, smaller-than-normal head and brain development, 
low birth weight, developmental delays, and other preg-
nancy and birth complications in infants born to women 
who inhaled solvents recreationally (Pearson et al., 1994). 
Tenebein (1993) described a neonatal withdrawal syn-
drome potentially attributable to maternal inhalant 
use. Recent laboratory studies also have demonstrated 
evidence of growth and developmental aberrations, 
physical deformities, and other adverse outcomes (e.g., 
Bowen et al., 2005; 2007; 2009; Bowen, Hannigan, 
and Cooper, 2009).While discussion of these findings is 
beyond the scope of this paper, they have been capably 
reviewed by Bowen and colleagues (2006), Lubman and 
colleagues (2008), and Hannigan and Bowen (2010).
NEUROBIOLOGY OF INHALANT USE 
Much has been learned during the past decade about 
inhalants’ pharmacological properties and effects (Bowen 
et al., 2006; Lubman, Yücel, and Lawrence, 2008). 
Although there has been limited research on the rein-
forcing properties of inhalants, animal studies suggest 
that several abused inhalants function as reinforcers (see 
Bowen et al., 2006, p. 643, for a review of findings). 
For example, in the conditioned place preference reward 
paradigm, toluene increases rats’ tendency to gravi-
tate to a chamber in which they formerly received the 
drug over one in which they did not (Lee, Schiffer, and 
Dewey, 2004). Of the few studies that have examined 
self-administration of inhaled compounds in nonhuman 
species, one demonstrated that mice will self-administer 
intravenous toluene and TCE (Blokhina et al., 2004), 
and another has shown that rats will self-administer ether 
vapor (Pogorelov and Kovalev, 1999). Other investiga- Pogorelov and Kovalev, 1999). Other investiga- ). Other investiga-
tions have demonstrated that nonhuman primates will 
self-administer chloroform, ether, nitrous oxide, and 
toluene (see Evans and Balster, 1991).
Toluene and TCE appear to produce motor excita-
tion at low concentrations and sedation, anesthesia, 
coma, and death at higher concentrations (Bowen and 
Balster, 1998). Benzene and diethyl ether also produce 
tranquilizing effects (Bowen, Wiley, and Balster, 1996; 
Paéz-Martinez, Cruz, and López-Rubalcava, 2003). 
Bowen and colleagues (2006) concluded that “the anx-
iolytic [anxiety reducing] effects of solvents are not an 
unexpected finding since these compounds, like other 
[central nervous system] depressants, act as positive 
modulators of GABAA receptors… [W]hat remains 
unclear is whether other solvents share these anxiolytic 
properties, the relative potencies to produce these effects, 
and whether tolerance (or sensitization) develops after 
chronic binge exposure.” 
The neuropharmacological effects of these solvents 
do not appear to be limited to modulation of the GABA 
receptor. Drug-discrimination studies using laboratory 
animals (Bowen et al., 1999) have shown that toluene 
can induce subjective effects similar to those of the psy-
chedelic anesthetic phencyclidine (PCP), suggesting 
that toluene, like PCP, may block the NMDA recep-
tor. It should be noted, however, that toluene failed to 
induce subjective effects similar to those of dizocilpine, 
another selective NMDA receptor blocker, in a similar 
drug-discrimination study (Shelton and Balster, 2004). 
In support of these behavioral results, recent in vitro 
studies have demonstrated that several abused inhal-
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ants act with varying affinity and efficacy at a number 
of molecular sites. Toluene appears to cause its cen-
tral nervous system depressant effects in large part by 
noncompetitively preventing glutamate stimulation 
of NMDA NR1 and NR2B receptor subtypes (Bale et 
al., 2005; Cruz et al., 1998), and prolonged exposure 
to toluene increases levels of brain NMDA receptors 
(Williams, Stafford, and Steketee, 2005). Other solvents, 
including benzene, ethylbenzene, propylbenzene, TCE, 
and xylene, also antagonize the NMDA receptor (Cruz, 
Balster, and Woodward, 2000; Raines et al., 2004).
A recent study showed that toluene and alcohol 
exert opposite effects on two channels that mediate the 
passage of potassium into and out of brain cells (the 
large-conductance calcium-activated potassium channel 
and G protein–coupled inwardly rectifying potassium 
channel). Alcohol excites these channels, but toluene 
inhibits them, a finding that eliminates them as likely 
candidates to underlie effects that toluene and alcohol 
produce in common (Del Re, Dopico, and Woodward, 
2006). Exposure to toluene increases dopamine levels 
in the rat prefrontal cortex and striatum and increases 
neuronal firing in the ventral tegmental area in a man-
ner similar to other drugs of abuse, effects that could 
be integral to the rewarding effects of toluene (Riegel 
and French, 1999; 2002; Riegel et al., 2004; 2007).   
Gerasimov and colleagues (2002; 2005) demonstrated 
that radioactively labeled toluene, butane, and acetone 
were rapidly taken up and cleared from areas such as the 
striatal and frontal brain regions of nonhuman primates. 
SCREENING AND ASSESSMENT
Systematic screening and assessment of inhalant use 
would facilitate earlier and more effective prevention and 
treatment, but clinicians appear to have a low index of 
suspicion for inhalant use and related problems (Ander-
son and Loomis, 2003). A few attempts have been made 
internationally to develop paper-and-pencil screening 
assessments of inhalant use, but these instruments are 
of limited utility for U.S. practitioners (e.g., Ogel et 
al., 2005). Howard and colleagues (2008) prepared 
the Volatile Solvent Screening Inventory (VSSI) and 
Comprehensive Solvent Assessment Interview (CSAI). 
The VSSI is freely available, requires approximately 20 
minutes to complete, and assesses past-year and lifetime 
frequency of use of 55 inhalant chemicals and products, 
medical history, demographic characteristics, current 
psychiatric symptoms, suicidal thoughts and attempts, 
trauma history, temperamental traits such as impulsivity, 
and the frequency and nature of antisocial behavior in 
the prior year. The CSAI is also free, requires 20 to 90 
minutes to complete (depending on the extent of the 
reported history of inhalant use), and assesses reasons 
for starting and stopping inhalant use; typical modes, 
locations, contexts and subjective effects of use; adverse 
acute consequences of inhalant intoxication; perceived 
risks of inhalant use; estimated likelihood of future use; 
sibling and friends’ inhalant use; and DSM-IV inhalant 
abuse and dependence criteria. The reader can access 
these instruments on the Internet: dx.doi.org/10.1016/j.
drugalcdep.2007.08.023 (Howard et al., 2008).
Efforts are under way to improve laboratory diagnosis 
of inhalant use and abuse (e.g., Chakroun et al., 2008; 
Thiesen, Noto, and Barros, 2007), but such tests are not 
yet widely available, nor have they been implemented in 
routine clinical practice. Findings from the occupational 
toxicology and inhalant abuse literature suggest that 
bioassays for hippuric acid, o-cresol levels, and benz-
ylmercapturic acid may eventually be useful urinary 
markers of toluene abuse (Broussard, 2000; Chakroun 
et al., 2008; Çök, Dagdelen, and Gökçe, 2003; Inoue 
et al., 2004; Ukai et al., 2007).
TREATMENT AND PREVENTION
Few studies have examined pharmacological or psycho-
social interventions for those who use inhalants or who 
have inhalant-induced disorders. Reasons for the lack 
of studies are unclear. Drug abuse researchers may have 
been slow to recognize the importance of inhalant use 
disorders, perhaps because of the stigmatized nature of the 
behavior. Studies may be difficult to execute because of 
the social disenfranchisement of inhalant users and their 
frequent residence in locations that are geographically 
isolated (e.g., rural settings or reservations) or inhospi-
table to clinical research (e.g., juvenile or criminal justice 
facilities or psychiatric hospitals). In addition, people who 
have inhalant use disorders may be difficult to recruit, 
assess, and follow because they are typically dependent 
on multiple drugs and afflicted with comorbid mood, 
anxiety, and personality disorders. 
Treatment programs that specialize in inhalant 
dependence are almost nonexistent in the United States; 
only one, the Tundra Swan Inhalant Treatment Program 
of the McCann Treatment Center in Bethel, Alaska, is 
currently operating. This center is administered by the 
Yukon-Kuskokwim Health Corporation and serves 
15 to 19 youths at a time, who range in age from 10 
to 18 years and reside mostly in nearby rural Alaskan 
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areas. Treatment services include traditional indigenous 
cultural practices, such as native dancing, crafts, and 
sweat lodges, and intensive family involvement. No 
formal evaluations of the Tundra Swan program have 
been published.
Nevertheless, substance abuse treatment practitioners 
express a desire for specialized training in inhalant-related 
assessment and treatment. Beauvais and colleagues (2002) 
surveyed 550 program directors in the United States: 
nearly three-quarters (73.9 percent) responded that 
inhalant abusers were somewhat-to-substantially more 
difficult to treat compared with abusers of other drugs, 
and only 15.1 percent thought current training resources 
were sufficient. A large survey of agencies serving young 
people in Wisconsin reported similar findings: 40.6 
percent of respondents indicated that inhalant abusers 
exhibit brain impairments and medical, family, and 
developmental concerns that are more severe than those 
of other drug abusers (Malesevich and Jadin, 1995). 
Survey respondents tended to believe that detoxification 
and treatment stays should be longer for inhalant abus-
ers than for abusers of other psychoactive drugs. Given 
the substantial prevalence and serious consequences 
of inhalant abuse and the virtual absence of specialty 
inhalant treatment programs in the United States, it is 
important that practitioners become aware of current 
inhalant screening and treatment approaches.
  
Pharmacological Interventions 
Pharmacologic treatments for inhalant use disorders have 
rarely been evaluated. A few studies have documented 
reductions in psychotic symptoms in inhalant abusers, 
although it is not clear whether the psychoses were due 
to or simply comorbid with the inhalant abuse: 
•	Misra,	Kofoed,	and	Fuller	(1999)	reported	successful	
use of risperidone to treat paranoid psychosis in a 
25-year-old Caucasian man who had been inhaling 
gasoline and carburetor cleaner almost daily for 5 
years and who had failed to fully respond to prior 
trials with thioridazine and divalproex. Risperidone 
given at a dosage of 0.5 mg twice daily for 4 weeks 
reduced auditory and visual hallucinations, paranoia, 
and aggressive behavior. When the dose of risperidone 
was increased to 1 mg twice daily, craving for inhalants 
was significantly reduced, paranoid ideation ceased, 
and continuous abstinence from inhalants was main-
tained for 12 weeks. The researchers recommended 
that risperidone be studied further as a treatment for 
craving in inhalant-dependent people. 
•	Hernandez-Avila	and	colleagues	(1998)	conducted	a	
randomized trial with 40 psychotic men with histories 
of inhalant abuse who were treated with either halo-
peridol or carbamazepine. After 5 weeks of treatment, 
the men in both the carbamazepine and haloperidol 
groups showed reductions in symptom severity of 48.3 
percent and 52.7 percent, respectively, on the Brief 
Psychiatric Rating Scale. The investigators concluded 
that approximately half of the patients in each arm of 
the study responded to treatment, but that carbam-
azepine caused fewer side effects.
One case report and one preclinical study have 
reported positive but very preliminary evidence of 
potentially effective pharmacotherapies for inhalant 
dependence. Shen (2007) described the successful treat-
ment of a 21-year-old man who had been using inhalants 
for 4 years but had no history of other substance abuse 
problems. When treated with 100 mg of lamotrigine 
daily, the subject reported fewer cravings for inhalants 
and achieved 6 months of continuous abstinence without 
significant side effects from the medication. Lee, Schiffer, 
and Dewey (2004) reported preclinical evidence sug-
gesting that vigabatrin, a selective GABA transaminase 
inhibitor, could be an effective treatment for inhalant 
dependence. 
Psychosocial Interventions 
Few psychosocial interventions have been tested with 
inhalant users in the United States. Holistic approaches 
incorporating elements of traditional indigenous cultures 
have reportedly been used successfully in Canada (Dell, 
Dell, and Hopkins, 2005; YSAC Annual Report, 2007) 
and with aboriginal populations in Australia (Preuss 
and Brown, 2006). Demand-reduction interventions—
including community-based approaches, education, 
youth and recreation programs, clinical management 
and counseling, and residential programs—were compre-
hensively evaluated in a recent Australian report (d’Abbs 
and MacLean, 2008). The relevance of these findings to 
an American context is uncertain. The recommenda-
tion that treatment be broadly focused on the diverse 
problems of inhalant users is certainly sensible, as are the 
notions that aftercare and family involvement are crucial. 
D’Abbs and MacLean (2008) addressed the highly 
controversial topic of harm reduction interventions. 
These interventions have, for example, encouraged 
inhalant users to avoid covering their heads with plas-
tic bags to prevent accidental asphyxiation; sniff from 
containers with small surface areas; avoid inhalation in 
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enclosed places or in hazardous places such as next to busy 
roadways; inhale under supervision; take precautions to 
avoid burns, overdose, and aspiration of vomitus; and 
avoid inhalants such as butane and propane that pose 
heightened risk for sudden death. Ethnographic studies 
indicate that some inhalant users take the initiative to 
minimize risks associated with their inhalant use (San-
dover, Houghton, and O’Donoghue, 1997).
Broadly focused biopsychosocial treatment interven-
tions may well be critically important given the manifold 
problems of inhalant abusers. Outreach to homeless 
young people and adults, youths who have dropped 
out of school or who are frequently truant, people in 
juvenile or adult correctional facilities or psychiatric 
hospitals, and inhalant abusers who are not actively 
seeking treatment is critical. 
Additional treatment research is also critical, because 
current findings suggest that inhalant abusers may have 
comparatively poor treatment outcomes (e.g., Sakai, 
Mikulich-Gilbertson, and Crowley, 2006). 
Prevention
Prevention approaches targeted to inhalant use are 
uncommon and have not always been successful (e.g., 
Brown et al., 2007; Collins, Johnson, and Becker, 2007; 
Furr-Holden et al., 2004). However, several promis-
ing prevention strategies have been identified in recent 
years. Schinke and colleagues evaluated correlates of 
inhalant use among adolescent girls and subsequently 
reported significantly reduced inhalant use at a 2-year 
followup in a randomized controlled trial of a gender-
specific, computer-delivered prevention intervention 
for adolescent girls and their mothers (Schinke, Fang, 
and Cole, 2008; 2009). 
An innovative, integrated approach to inhalant use 
prevention involving community mobilization efforts, 
environmental strategies, and school-based activities 
was described by Johnson and colleagues at the Pacific 
Institute for Research and Evaluation. They describe 
results of a related feasibility evaluation (Johnson et al., 
2007), explain how the environmental component—
designed to reduce retailers’ sales of inhalants—can be 
implemented and evaluated (Courser et al., 2007), and 
present positive findings from a randomized controlled 
evaluation of the intervention, which was implemented 
in frontier Alaskan communities (Johnson et al., 2009). 
These reports and others that present positive findings 
regarding inhalant prevention (e.g., Spoth et al., 2007) 
suggest that comprehensive, theory-informed, and 
gender-specific prevention approaches may be effec-
tive methods for inhalant use prevention.
Supply-side interventions have not been widely 
applied in the United States, but in Australia they have 
included adding “bittering” agents to frequently abused 
inhalant products, selling gasoline substitutes such as 
aviation fuel or Opal gas that are not readily abused, and 
modifying products so that they are no longer sought 
out by abusers of inhalants.
 
CONCLUSIONS 
More than 22 million Americans age 12 and older have 
used inhalants, and more than three-quarters of a million 
become new users annually. Inhalant use may lead to 
inhalant abuse or dependence in less than 10 percent to 
nearly 50 percent of cases, depending on the characteris-
tics of the population studied. There are many acute and 
long-term consequences of inhalant use and these can 
be catastrophic, but far more needs to be learned about 
the full range of maladies associated with use of specific 
inhalant products and factors that increase vulnerability 
for these disorders.
Although some inroads have been made in under-
standing the pharmacology and neurobiology of inhal-
ant abuse during the past decade, more needs to be 
learned about similarities and differences of specific 
abused inhalants. Ethnographic reports suggest that many 
youths abuse inhalants in order to achieve a euphoric 
state (d’Abbs and MacLean, 2008); survey findings con-
firm that young people intentionally abuse inhalants to 
produce intoxication (Howard et al., 2008); and operant 
conditioning and other laboratory paradigms suggest that 
inhalants may act as reinforcers in much the same way 
as other drugs of abuse (Bowen et al., 2006).
Practitioners should maintain a high index of suspi-
cion for inhalant use, screen for inhalant use and inhalant 
use disorders, and intervene early in the course of the 
disorder with educational interventions and approaches 
that have been used in the treatment of other substance 
use disorders (e.g., motivational enhancement and relapse 
prevention interventions). This approach seems reason-
able until researchers develop and fully evaluate effective 
evidence-based interventions for inhalant abusers. Given 
the high prevalence of conduct, substance use, mood, 
anxiety, and personality disorders among inhalant abus-
ers, it is important that practitioners also avail themselves 
of evidence-based interventions for these commonly 
co-occurring conditions (Hepner et al., 2007; Woolgar 
and Scott, 2005).
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